KMTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends April 30

KESTRA MEDICAL TECHNOLOGIES, LTD.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$29.37+2.13 (+7.82%)

Close on Oct 19, 2026

Market cap: $1.72B
P/E (TTM): –
Dividend yield: –

KESTRA MEDICAL TECHNOLOGIES, LTD. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-04-30	FY 2025 2025-04-30	FY 2024 2024-04-30
Revenue	95	60	28
Cost of Revenue	46	36	27
Gross Profit	49	24	0.36
Research & Development	19	16	15
Selling, General & Admin	164	115	70
Operating Expenses	184	131	85
Operating Income	-135	-106	-85
Interest Expense	7.55	7.73	6.23
Interest & Investment Income	8.35	3.20	–
Other Non-Operating Income	2.62	-2.77	-2.80
Gain (Loss) on Investments	0	0	–
Gain (Loss) on Sale of Assets	-1.16	-1.34	-1.07
Pretax Income	-131	-114	-94
Income Tax Expense	0.29	0.14	0.02
Net Income incl. Noncontrolling Interests	-132	-114	-94
Net Income	-132	-114	-94
Preferred Dividends	–	12	6.72
Net Income to Common	-132	-126	-101
EPS (Basic)(per share)	-2.43	-5.13	-5.07
EPS (Diluted)(per share)	-2.43	-5.13	-5.07
Shares Outstanding (Basic, Weighted)(shares)	54	25	20
Shares Outstanding (Diluted, Weighted)(shares)	54	25	20
EBITDA	-126	-98	-74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: 53.9%
Operating margin: -134.5%
Net margin: -140.4%
Return on equity, FY2026: –

Financial strength

Current ratio: 4.69
Debt to equity: –
Debt to assets: 20.9%
Cash to current liabilities: 142.0%

Valuation

P/E ratio: –
Price to sales: 16.12
Price to book: –
Dividend yield: –